| 4.64 0.07 (1.53%) | 09-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.55 | 1-year : | 6.49 |
| Resists | First : | 4.76 | Second : | 5.55 |
| Pivot price | 4.52  |
|||
| Supports | First : | 4.36 | Second : | 4.11 |
| MAs | MA(5) : | 4.63 |
MA(20) : | 4.47 |
| MA(100) : | 3.98 |
MA(250) : | 5.13  |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.8 |
D(3) : | 73.8 |
| RSI | RSI(14): 60.6 |
|||
| 52-week | High : | 7.96 | Low : | 3.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDXG ] has closed below upper band by 23.4%. Bollinger Bands are 6.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.67 - 4.69 | 4.69 - 4.71 |
| Low: | 4.51 - 4.53 | 4.53 - 4.55 |
| Close: | 4.6 - 4.64 | 4.64 - 4.68 |
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Tue, 08 Sep 2026
Two New York conferences will include MIMEDX executives on Sept. 9 and 10 - Stock Titan
Tue, 08 Sep 2026
MIMEDX GROUP, INC. SEC Filing (Sep 8, 2026) - Stock Titan
Thu, 30 Jul 2026
MiMedx Group: Sanara Deal Comes At A Poor Time - Seeking Alpha
Wed, 29 Jul 2026
MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Wed, 29 Jul 2026
MIMEDX to Acquire Sanara MedTech - GlobeNewswire
Wed, 29 Jul 2026
MIMEDX Group (NASDAQ:MDXG) Shares Fall After Q2 Revenue and EPS Slightly Miss Estimates - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 146 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 77.6 (%) |
| Shares Short | 8,890 (K) |
| Shares Short P.Month | 7,520 (K) |
| EPS | 0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.48 |
| Profit Margin | 1.7 % |
| Operating Margin | -28.7 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 2.8 % |
| Qtrly Rev. Growth | -34.8 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 2.43 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 46 (M) |
| Levered Free Cash Flow | 41 (M) |
| PE Ratio | 116 |
| PEG Ratio | 2.8 |
| Price to Book value | 3.13 |
| Price to Sales | 1.9 |
| Price to Cash Flow | 14.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|